Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL
Authors:
Open Access
- 14 April 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Abstract
The use of chimeric antigen receptor (CAR) T lymphocytes in the treatment of refractory or relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL) has meant a radical change in the prognosis of these patients, whose chances of survival with conventional treatment are very low. The current probability of event-free survival by R/R B-ALL patients treated using anti-CD 19 CART cell therapy is as high as 50-60% at 1.5 years, which is a very important advance for this group of very ill patients. Although most patients (70 to 94%) achieve complete remission (CR), the main problem continues to be relapse of the disease. Most relapses, both in clinical trials and real-world evidence, are due to failure of CAR-T cell expansion or limited CAR-T persistence. However, despite the adequate functioning of infused CART lymphocytes, the tumor cells of an important group of patients manage to evade CAR-T attack, resulting in a CD 19-negative relapse. Several mechanisms have been described that may be able to produce the escape of leukemic cells, such as acquired mutations and alternative splicing of the CD19 antigen, CD19 epitope loss or masking, leukemia lineage switching, and trogocytosis. In the present review, we comprehensively analyze the leukemic cell escape mechanisms, the incidence of CD19-negative relapse reported in clinical trials and real-world evidence (outside clinical trials), and provide an update on the main lines of current research into the prevention of leukemia evasion.Keywords
This publication has 96 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology & Oncology, 2012
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioningBlood, 2012
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 2011
- Expansion of the eukaryotic proteome by alternative splicingNature, 2010
- CD22 and Siglec‐G: B‐cell inhibitory receptors with distinct functionsImmunological Reviews, 2009
- Alternative isoform regulation in human tissue transcriptomesNature, 2008
- CongenitalMLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangementLeukemia & Lymphoma, 2005
- The biological and clinical significance of MLL abnormalities in haematological malignanciesEuropean Journal of Clinical Investigation, 2004
- What is trogocytosis and what is its purpose?Nature Immunology, 2003